Managing clinical friction points If clinicians are to leverage GLP-1RAs, they must manage practical friction points
This work highlights OmniAb, Inc.s deep expertise in ion channel drug discovery, leveraging our fully integrated electrophysiologybased screening platform
Strengths and weaknesses The strengths of this substudy include the methods and design of SUSTAIN 8, a double-blind randomised clinical trial with a global population, relatively long treatment period of 52 weeks, and relevant head-to-head comparison with a glucose-lowering medication with demonstrated efficacy in type 2 diabetes
Brand-name semaglutide (Ozempic, Wegovy) and brand-name tirzepatide (Mounjaro, Zepbound) use proprietary formulation buffers, preservatives, and pH adjusters that have been optimized through extensive pharmaceutical development
As research continues and more data accumulates, this innovative therapy could redefine how we approach weight management and its associated health benefits